Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation protects at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by stimulating the mother’s body’s defences to generate defence proteins, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.

• Nearly 85 per cent coverage when vaccinated four weeks before birth
• Antibodies from the mother passed through the placenta protect newborns from birth
• Coverage possible with two-week gap before premature birth
• Vaccination during the third trimester still provides significant infant protection

Compelling evidence from current research

The efficacy of the pregnancy RSV vaccine has been demonstrated through a extensive research programme carried out throughout England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month period, providing robust and representative evidence of the vaccine’s actual performance. The study’s results have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and expectant parents with confidence in the vaccine’s proven efficacy across varied populations and settings.

The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This marked difference underscores the vaccine’s critical role in preventing serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.

Methodology and scope of study

The research analysed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospital admissions. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or small subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology measured practical outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine performs when given across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and its threats

Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection causes inflammation deep within the lungs and airways, making it dangerously difficult for infected babies to feed and breathe adequately. Parents commonly see their babies fighting for breath, their chests rising whilst they attempt to draw adequate oxygen into their compromised lungs. Whilst the majority of babies improve through palliative treatment, a limited though important number die from RSV-related complications yearly, making prevention through vaccination a critical public health priority for protecting the youngest and most at-risk members of society.

• RSV causes lung inflammation, causing serious respiratory problems in infants
• Approximately half of newborns contract the virus during their first few months alive
• Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
• More than 20,000 UK babies require serious hospital care for RSV each year
• Few babies die from RSV related complications each year in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme commenced in 2024, health officials have stressed the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies via the placenta.

The messaging from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.

Regional differences in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among eligible pregnant women, whilst others remain focused to boost understanding and availability of the jab. These geographical variations demonstrate variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics shows consistently strong protection regardless of geographical location.

• NHS trusts launching varied communication campaigns to engage with expectant mothers
• Regional disparities in vaccine uptake rates in different parts of England demand focused enhancement
• Regional health providers modifying schemes to align with community needs and circumstances

Real-world impact and parental perspectives

The vaccine’s impressive effectiveness delivers tangible benefits for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the introduction of this protective measure, the 80% drop in admissions means thousands of infants protected against serious illness. Parents no more face the upsetting situation of seeing their babies struggle for breath or labour to feed, symptoms that characterise severe RSV infections. The vaccine has markedly changed the terrain of neonatal breathing health, offering expectant mothers a active means to shield their most at-risk babies during those vital initial period.

For families like that of Malachi, whose acute RSV infection caused devastating brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s support of the jab highlights the profound consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to pregnant women navigating their final trimester, transforming what was once an inevitable seasonal threat into a controllable health concern.